Protection against ischemic hippocampal CA1 damage in the rat with a new non-NMDA antagonist, NBQX

Acta Neurol Scand. 1992 Jul;86(1):45-9. doi: 10.1111/j.1600-0404.1992.tb08052.x.

Abstract

Two glutamate antagonists were tested in a rat model of complete, transient cerebral ischemia. Six days after 10 min ischemia the mean loss of hippocampal CA1 pyramidal neurones was 73%. Administration of the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) antagonist NBQX (2,3-dihydro-6-nitro-7-sulfamoyl-benzo(F)quinoxaline) reduced the pyramidal neurone loss to 1%, 11% and 15%, when given before, immediately after or 1 h after ischemia, respectively. MK-801 (dizocilpine), a competitive NMDA antagonist gave no protection in this model. We suggest that the AMPA receptor transduction mechanisms are sensitized by ischemia and that the postischemic blockade of the main glutamatergic input to the CA1 cells with NBQX impairs the deleterious effect of "normal" postischemic excitatory transmission.

MeSH terms

  • Animals
  • Brain Damage, Chronic / pathology*
  • Brain Ischemia / pathology*
  • Cell Count
  • Hippocampus / blood supply*
  • Hippocampus / pathology
  • Male
  • Nerve Degeneration / drug effects*
  • Nerve Degeneration / physiology
  • Neurons / drug effects
  • Neurons / pathology
  • Quinoxalines / pharmacology*
  • Rats
  • Rats, Inbred Strains
  • Receptors, AMPA
  • Receptors, Glutamate
  • Receptors, N-Methyl-D-Aspartate / drug effects*
  • Receptors, N-Methyl-D-Aspartate / physiology
  • Receptors, Neurotransmitter / drug effects*
  • Receptors, Neurotransmitter / physiology

Substances

  • Quinoxalines
  • Receptors, AMPA
  • Receptors, Glutamate
  • Receptors, N-Methyl-D-Aspartate
  • Receptors, Neurotransmitter
  • 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline